UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline

Journal of clinical oncology, 2019-07, Vol.37 (20), p.1753-1774

2019

Volltextzugriff (PDF)

A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer

Clinical cancer research, 2020-02, Vol.26 (4), p.837-845

2020

Volltextzugriff (PDF)

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105

Cancer discovery, 2019-03, Vol.9 (3), p.384-395

2019

Volltextzugriff (PDF)

Postoperative Combined Modality Treatment in High Risk Resected Locally Advanced Squamous Cell Carcinomas of the Head and Neck (HNSCC)

Frontiers in oncology, 2018-12, Vol.8, p.588-588

2018

Volltextzugriff (PDF)

Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors

Cancer medicine (Malden, MA), 2023-04, Vol.12 (8), p.9384-9391

2023

Volltextzugriff (PDF)

Multi-agent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderly

Head & neck, 2012-08, Vol.34 (8), p.1147-1152

2012

Volltextzugriff (PDF)

Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients

Cancer medicine (Malden, MA), 2022-11, Vol.11 (22), p.4104-4111

2022

Volltextzugriff (PDF)

Concurrent cetuximab and postoperative radiation in resected high-risk squamous cell carcinomas of the head and neck: A single-institution experience

Head & neck, 2016-09, Vol.38 (9), p.1318-1323

2016

Volltextzugriff (PDF)

The mutational landscape of recurrent versus nonrecurrent human papillomavirus-related oropharyngeal cancer

JCI insight, 2018-07, Vol.3 (14)

2018

Volltextzugriff (PDF)

A phase I/II trial of concurrent immunotherapy with chemoradiation in locally advanced larynx cancer

Laryngoscope investigative otolaryngology, 2022-04, Vol.7 (2), p.437-443

2022

Volltextzugriff (PDF)

Salivary Gland Malignancies

Hematology/oncology clinics of North America, 2015-12, Vol.29 (6), p.1145-1157

2015

Volltextzugriff (PDF)

A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction

Investigational new drugs, 2012-08, Vol.30 (4), p.1684-1689

2012

Volltextzugriff (PDF)

Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: Impact of changing disease epidemiology on contemporary trial design

Head & neck, 2015-11, Vol.37 (11), p.1583-1589

2015

Volltextzugriff (PDF)

NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017

Journal of the National Comprehensive Cancer Network, 2017-06, Vol.15 (6), p.761-770

2017

Volltextzugriff (PDF)

A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma

Clinical cancer research, 2018-06, Vol.24 (12), p.2740-2748

2018

Volltextzugriff (PDF)

FOXM1 drives HPV+ HNSCC sensitivity to WEE1 inhibition

Proceedings of the National Academy of Sciences - PNAS, 2020-11, Vol.117 (45), p.28287-28296

2020

Volltextzugriff (PDF)

Oncologic outcomes of salvage surgery and immune checkpoint inhibitor therapy in recurrent head and neck squamous cell carcinoma: A single‐institution retrospective study

Head & neck, 2022-11, Vol.44 (11), p.2465-2472

2022

Volltextzugriff (PDF)

Current and Emerging Standards of Concomitant Chemoradiotherapy

Seminars in oncology, 2008-06, Vol.35 (3), p.211-220

2008

Volltextzugriff (PDF)

Immunotherapy for Head and Neck Cancer in the Era of Exponentially Increasing Health Care Expenditure

The oncologist (Dayton, Ohio), 2018-02, Vol.23 (2), p.147-149

2018

Volltextzugriff (PDF)

PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study

Oral oncology, 2024-02, Vol.149, p.106634-106634, Article 106634

2024

Volltextzugriff (PDF)

Neutrophil to lymphocyte ratio and peripheral blood biomarkers correlate with survival outcomes but not response among head and neck and salivary cancer treated with pembrolizumab and vorinostat

Head & neck, 2023-02, Vol.45 (2), p.391-397

2023

Volltextzugriff (PDF)

Radiation therapy for low‐ and high‐risk perineural invasion in head and neck cutaneous squamous cell carcinoma: Clinical outcomes and patterns of failure

Head & neck, 2023-09, Vol.45 (9), p.2323-2334

2023

Volltextzugriff (PDF)

The role of elective neck dissection in high‐grade parotid malignancy: A hospital‐based cohort study

The Laryngoscope, 2020-06, Vol.130 (6), p.1487-1495

2020

Volltextzugriff (PDF)

Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

JNCI : Journal of the National Cancer Institute, 2022-12, Vol.114 (12), p.1619-1627

2022

Volltextzugriff (PDF)

Wound Complications in Head and Neck Squamous Cell Carcinomas After Anti–PD‐1 Therapy

The Laryngoscope, 2019-12, Vol.129 (12), p.E428-E433

2019

Volltextzugriff (PDF)

1 – 25 von 1.121

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(996)
Mit Volltextzugriff
(993)

Publikationsform

Sprache

Englisch
(1.060)
Japanisch
(124)
Spanisch
(75)
Portugiesisch
(25)
Deutsch
(4)
Norwegisch
(2)

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline

A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105

Postoperative Combined Modality Treatment in High Risk Resected Locally Advanced Squamous Cell Carcinomas of the Head and Neck (HNSCC)

Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors

Multi-agent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderly

Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients

Concurrent cetuximab and postoperative radiation in resected high-risk squamous cell carcinomas of the head and neck: A single-institution experience

The mutational landscape of recurrent versus nonrecurrent human papillomavirus-related oropharyngeal cancer

A phase I/II trial of concurrent immunotherapy with chemoradiation in locally advanced larynx cancer

Salivary Gland Malignancies

A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction

Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: Impact of changing disease epidemiology on contemporary trial design

NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017

A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma

FOXM1 drives HPV+ HNSCC sensitivity to WEE1 inhibition

Oncologic outcomes of salvage surgery and immune checkpoint inhibitor therapy in recurrent head and neck squamous cell carcinoma: A single‐institution retrospective study

Current and Emerging Standards of Concomitant Chemoradiotherapy

Immunotherapy for Head and Neck Cancer in the Era of Exponentially Increasing Health Care Expenditure

PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study

Neutrophil to lymphocyte ratio and peripheral blood biomarkers correlate with survival outcomes but not response among head and neck and salivary cancer treated with pembrolizumab and vorinostat

Radiation therapy for low‐ and high‐risk perineural invasion in head and neck cutaneous squamous cell carcinoma: Clinical outcomes and patterns of failure

The role of elective neck dissection in high‐grade parotid malignancy: A hospital‐based cohort study

Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Wound Complications in Head and Neck Squamous Cell Carcinomas After Anti–PD‐1 Therapy

Suchergebnisse filtern